CROs offering Translational Research with Biologics (Monoclonal Antibodies)
29 published
29 published CROs match Translational Research and Biologics (Monoclonal Antibodies).
Locations in this set include United States, China, United Kingdom, Australia, India, and France.
Capabilities that show up most often in this set: Preclinical In Vivo Studies, In Vitro Pharmacology, In Vivo Efficacy Models, Preclinical In Vitro Studies, and In Vivo PK / PD Studies.
Matching companies
Premier ResearchPremier Research is a global full-service CRO delivering clinical research and development solutions across the complete drug development lifecycle. The organization provides comprehensive capabilities spanning study design, study startup, medical affairs, biostatistics and data management, central monitoring, clinical monitoring and site management, project and risk management, safety and pharmacovigilance, quality and compliance, and medical writing.
Proone LabsProone Labs provides preclinical pharmacology, drug discovery, and regulatory support services to biotech startups, traditional pharma, and in-silico companies. The team has delivered 30+ assays, 50+ cell lines, and supported 4 FDA drug approvals across multiple therapeutic areas.
Qoolabs, IncQoolabs specializes in rapid rabbit monoclonal antibody development using the QMAb™ platform, delivering highly specific antibodies with natural heavy-light chain pairing in 3–4 months from immunization.
Reaction BiologyGlobal preclinical CRO specializing in kinase drug discovery, cell-based assays, in vivo pharmacology, and immuno-oncology with 1,000+ cell lines and hundreds of validated protein targets across US and EU facilities.
Sussex Research Laboratories Inc.Global leader in carbohydrate and glycan synthesis, offering custom synthesis, CRO, and CDMO services for drug discovery and development. Specializes in GalNAc targeting ligands, glycopeptides, and glycoconjugates with over 25 years of expertise.
Syngene InternationalInnovation-led CRDMO offering integrated scientific services from early discovery through commercial manufacturing, with cGMP-compliant facilities, 5,200+ scientists, and a new 50,000-liter single-use bioreactor capacity in the U.S.
TRiCBIOTRiCBIO provides human organoid research services for efficacy, safety, mechanism and immune-context studies using PDO 2.0 and ALI platforms, supporting biopharma and CRO teams in candidate evaluation and translational research.
TigermedLeading global CRO providing end-to-end clinical trial services, preclinical development, medical device and IVD trials, regulatory affairs, and real-world evidence studies across 180+ offices serving 4,000+ customers.
WuXi AppTecGlobal CRDMO platform providing integrated end-to-end contract research, development, and manufacturing services across discovery, preclinical, clinical, and commercial phases for small molecules, peptides, oligonucleotides, and biologics across 30+ countries.
Markdown mirror: /explore/translational-research/biologics-monoclonal-antibodies.md